Covidien says it won CE Mark approval in the European Union for home use of its Nellcor bedside SpO2 patient monitoring system.
Covidien (NYSE:COV) said it won CE Mark approval in the European Union for home use of its Nellcor bedside SpO2 patient monitoring system.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Report: Medtronic readies $10B bond flotation for Covidien deal; Medtech mergers stayed strong in Q3; Sources: Philips attracts private equity bids for lighting unit; Medtronic, Covidien set timetable for shareholders meetings; Report: Actavis may buy Allergan for at least $60 billion
Medtronic and Covidien set the timetable for shareholder meetings to vote on their pending, $43 billion merger.
Pioneering live interview series from MassDevice.com will close its 2014 season this week in Irvine, Calif. with Masimo CEO Joe Kiani and Caroll Neubauer, CEO, B. Braun Medical.
DeviceTalks, the live interview series featuring thought leaders from the $126B medical technology industry, closes out its 2014 season on November 19, 2014 in Irvine, Calif. with a conversation focused on whether the medical device industry is doing enough to protect patients.
A Covidien study has shown that its new VenaSeal system is just as effective in treating chronic leg vein disorders as its ClosureFast ablation catheter.
Medtronic is reportedly preparing to float $10 billion worth of bonds to help fund its $43 billion acquisition of Covidien.
Here's a look at some of the top Wall Street stories for medical device companies this week: Medtronic inks $16B loan package for Covidien buyout; Second Sight eyes $32m IPO; The silver lining for healthcare in U.S. inversion rules; Survey: Hospitals clamp down on medical device expenses; Nevro boosts IPO to $126m